DNSP-11 10 mg research-grade lyophilized D-peptide powder supplied in a glass vial. DNSP-11 is a synthetic D-amino acid peptide designed as an antagonist of the Nogo-66 Receptor 1 (NgR1), a receptor implicated in myelin-associated inhibition of axonal regeneration in central nervous system research models.
Research Use Only: All products are intended exclusively for laboratory and scientific research. Not for human or veterinary use.
Purity
High-purity research grade
Form
Lyophilized D-peptide powder
Content
10 mg DNSP-11 per vial
Packaging
Glass vial with sterile closure
Storage
Store lyophilized at 2–8 °C (desiccated, protect from light)
Molecular formula
C93H153N31O22
Molecular weight
~2057.4 g·mol⁻¹
Sequence (D-amino acids)
Ac-[dNle]-[dGlu]-[dHis]-[dHis]-[dGln]-[dLys]-[dLeu]-[dArg]-[dPhe]-[dIle]-[dGlu]-[dDpr]-[dLys]-[dGly]-[dArg]-NH2
CAS number
To be confirmed
In laboratory workflows, lyophilized research peptides are typically handled with suitable sterile diluents such as bacteriostatic water (BAC). For a compatible research-only solvent, see
Bacteriostatic water – 10 ml .
Research Overview
DNSP-11 is a synthetic D-peptide designed to antagonize the Nogo-66 Receptor 1 (NgR1), a neuronal receptor that binds myelin-associated inhibitors such as Nogo-A, MAG and OMgp in central nervous system models. Engagement of NgR1 is associated with reduced axonal growth and regeneration after injury. In in vitro and in vivo laboratory systems, DSNP-11 is used as a tool compound to explore how blocking NgR1 can modulate neurite outgrowth, synaptic plasticity and recovery-related processes in models of CNS damage and repair.
Primary Research Areas
-
Nogo-66 Receptor (NgR1) antagonism: used in studies focused on disrupting NgR1 signaling initiated by myelin-associated inhibitors, to clarify receptor-dependent checkpoints that restrict axonal growth in central nervous system research models.
-
Axonal regeneration and neurite outgrowth: applied in neuron culture systems and organotypic preparations to investigate axonal extension, branching and growth cone dynamics when NgR1-mediated inhibition is experimentally reduced or blocked.
-
Synaptic plasticity and connectivity: incorporated into experimental designs examining how modulation of NgR1 affects synapse formation, spine morphology and plasticity markers in CNS circuits subjected to injury- or experience-dependent remodeling paradigms.
-
Spinal cord injury and stroke models: used as a tool compound in preclinical models of spinal cord injury, ischemic stroke and related CNS insults to study structural and functional recovery endpoints in the presence of NgR1 antagonism under controlled laboratory conditions.
-
Overcoming myelin-associated inhibition: evaluated in combination with other experimental strategies (e.g. growth factor delivery, rehabilitation paradigms) to explore synergistic approaches for overcoming myelin-associated growth inhibition in CNS repair research.
